TEVA vs. VTRS, BGNE, KRTX, RDY, BMRN, UTHR, SRPT, ALNY, GMAB, and CTLT
Should you be buying Teva Pharmaceutical Industries stock or one of its competitors? The main competitors of Teva Pharmaceutical Industries include Viatris (VTRS), BeiGene (BGNE), Karuna Therapeutics (KRTX), Dr. Reddy's Laboratories (RDY), BioMarin Pharmaceutical (BMRN), United Therapeutics (UTHR), Sarepta Therapeutics (SRPT), Alnylam Pharmaceuticals (ALNY), Genmab A/S (GMAB), and Catalent (CTLT). These companies are all part of the "pharmaceutical preparations" industry.
Teva Pharmaceutical Industries (NYSE:TEVA) and Viatris (NASDAQ:VTRS) are both large-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, valuation, dividends, profitability, institutional ownership, community ranking, media sentiment, earnings and analyst recommendations.
Teva Pharmaceutical Industries received 1287 more outperform votes than Viatris when rated by MarketBeat users. Likewise, 67.53% of users gave Teva Pharmaceutical Industries an outperform vote while only 35.59% of users gave Viatris an outperform vote.
In the previous week, Teva Pharmaceutical Industries had 5 more articles in the media than Viatris. MarketBeat recorded 7 mentions for Teva Pharmaceutical Industries and 2 mentions for Viatris. Viatris' average media sentiment score of 1.20 beat Teva Pharmaceutical Industries' score of 0.88 indicating that Viatris is being referred to more favorably in the news media.
Teva Pharmaceutical Industries presently has a consensus price target of $13.78, indicating a potential upside of 3.98%. Viatris has a consensus price target of $11.00, indicating a potential downside of 4.10%. Given Teva Pharmaceutical Industries' stronger consensus rating and higher probable upside, research analysts clearly believe Teva Pharmaceutical Industries is more favorable than Viatris.
Viatris has a net margin of 0.35% compared to Teva Pharmaceutical Industries' net margin of -3.33%. Teva Pharmaceutical Industries' return on equity of 34.90% beat Viatris' return on equity.
Viatris has lower revenue, but higher earnings than Teva Pharmaceutical Industries. Teva Pharmaceutical Industries is trading at a lower price-to-earnings ratio than Viatris, indicating that it is currently the more affordable of the two stocks.
54.1% of Teva Pharmaceutical Industries shares are owned by institutional investors. Comparatively, 79.9% of Viatris shares are owned by institutional investors. 0.6% of Teva Pharmaceutical Industries shares are owned by insiders. Comparatively, 0.3% of Viatris shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Teva Pharmaceutical Industries has a beta of 1.05, suggesting that its share price is 5% more volatile than the S&P 500. Comparatively, Viatris has a beta of 1.13, suggesting that its share price is 13% more volatile than the S&P 500.
Summary
Teva Pharmaceutical Industries beats Viatris on 10 of the 18 factors compared between the two stocks.
Get Teva Pharmaceutical Industries News Delivered to You Automatically
Sign up to receive the latest news and ratings for TEVA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TEVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Teva Pharmaceutical Industries Competitors List
Related Companies and Tools
